2018 Press Releases

Keyword Search
 

May 17, 2018

Protagonist Therapeutics Announces Two Oral Presentations Accepted for 23rd Congress of the European Hematology Association read more

May 16, 2018

Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors read more

May 09, 2018

Protagonist Therapeutics Reports First Quarter 2018 Financial Results read more

May 03, 2018

Protagonist Therapeutics Announces Oral Presentation Accepted for Digestive Diseases Week Conference read more

March 26, 2018

Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis read more

March 09, 2018

Protagonist Therapeutics to Participate in the 28th Annual Oppenheimer Healthcare Conference read more

March 07, 2018

Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results read more

March 06, 2018

FDA Grants Orphan Drug Designation for Protagonist Therapeutics' PTG-300 for the Treatment of Beta-Thalassemia read more

March 01, 2018

Protagonist Therapeutics to Participate in the Barclay's Global Healthcare Conference read more

March 01, 2018

Protagonist to Announce Fourth Quarter and Year-End 2017 Financial Results on March 7, 2018; Year-End Update Call to Follow read more

January 31, 2018

Protagonist Therapeutics to Participate in the Leerink Partners 7th Annual Global Healthcare Conference read more

January 04, 2018

Protagonist Therapeutics Granted Two New US Patents for Peptide Drug Candidates PTG-100 and PTG-300 read more